Article

CURE's Top 5 Stories: March 2019

Here are the top 5 CURE stories for March 2019.

Here are the top 5 CURE stories for March 2019.

5. FDA Approves First Immunotherapy For Breast Cancer

In early March, the Food and Drug Administration (FDA) approved the frontline combination of Tecentriq (atezolizumab) plus Abraxane (nab-paclitaxel) for patients with unresectable locally advanced or metastatic PD-L1—positive triple-negative breast cancer.

4. Supporting Others Who Are Dealing With Cancer

People adjusting to cancer need space, but they also need to know they are loved and cared for. Here, one survivor shares her suggestions on how to talk with someone who is coping with their own diagnosis.

3. Immune-Boosting Foods

In this new feature of CURE’s sister publication, Heal, an expert from John Theurer Cancer Center shares three recipes filled with powerful germ-fighting, health-promoting properties.

2. Blood Cancers’ Bottom Line

We take a closer look at the high out-of-pocket medical care costs that patients with blood cancer and their families face in this piece.

1. Please Stop Calling It Hospice When I’m Very Much Alive

One is meant to improve quality of life and the other is end-of-life care. Yet palliative and hospice care still continue to be confused not only by patients, but also providers, as contributor Sarah DeBord details in her latest blog.

And as always, for links to all of our top stories and more, visit curetoday.com.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Image of Dr. Evens.
Image of carly.
Image of kelly.
Image of doctor.
Image of Dr. Kelly
image of doctor D'Sa
Picture of Dr. Pouneh Razavi
Related Content